Dana dhuwit saben saham Larimar Corp (LRMR)

Lambang korporat lan logo Larimar Therapeutics (LRMR)

Biotech development relies on the success of clinical trials, while the 1.49 level reflects current liquidity. Larimar Therapeutics (LRMR) is creating a treatment system for rare genetic brain pathologies via protein delivery. The cash per share figure confirms financial stability. Robotic platforms and AI automate drug discovery, which proves the technological superiority of Larimar Therapeutics (LRMR) on the chart.

Larimar Therapeutics Inc (LRMR): Dana dhuwit saben saham saka 04.07.2022 nganti 20.11.2026

Rincian analitis perusahaan Larimar Therapeutics

- rega pasar lan target rega analis:
- rincian posisi dhuwit lan arus kas:
Ringkesan analisis perusahaan:LRMR, Larimar Corp
Produk asil prodhuksi Larimar Therapeutics, Inc.

Larimar Therapeutics (LRMR) develops innovative drugs for the therapy of rare genetic pathologies, which requires significant capital expenditures for a diversified clinical trial pipeline. By analyzing the cash runway per share, an investor assesses the volume of net liquid assets per security, which determines the business's financial resilience and the company's horizon for autonomous operation without raising external capital.